Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04125290 · ClinicalTrials.gov registry record
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
A clinical trial, sponsored by AstraZeneca.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04125290 is a clinical trial that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2 participants.
The verdict
NCT04125290 was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment defined as an estimated GFR of 30-59 ml/min
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2021-06-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04125290
The ClinicalTrials.gov registry entry for NCT04125290 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04125290 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04125290 about?
NCT04125290 is a clinical study titled "US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)". This study is being conducted to satisfy a post-marketing requirement (PMR) to provide evidence characterizing 1) the safety of moxetumomab pasudotox-tdfk in patients who are 65 years of age and older and/or 2) the safety of moxetumomab pasudotox-tdfk in patients who have moderate renal impairment d...
What is the current status of trial NCT04125290?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-12-09. Estimated completion is 2021-06-21.
Who is sponsoring clinical trial NCT04125290?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.